Abstract
The effectiveness of the World Health Organization's (WHO) treatment category II regimen for tuberculosis in 124 patients was compared to that of 1147 patients receiving treatment category I in Lima, Peru following WHO's guidelines. Drug susceptibility test was available for 85% of patients. Prevalence of multi drug resistance and streptomycin resistance were 5.1% and 20.7%, respectively. Overall cure rate for regimen II was lower than that of regimen I: 67.8% (95% CI: 58.9-75.6.) vs 77.8% (95% CI: 75.3-80.2), p = 0.014. Multi-drug resistance exerted a profound effect on cure rates in both regimens. Our results support the phasing-out of treatment category II regimen in Peru.
| Original language | English |
|---|---|
| Pages (from-to) | 508-510 |
| Number of pages | 3 |
| Journal | Transactions of the Royal Society of Tropical Medicine and Hygiene |
| Volume | 106 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 2012 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Drug therapy
- Failure
- Multi-drug resistance
- Streptomycin
- Treatment outcome
- Tuberculosis
Fingerprint
Dive into the research topics of 'Additional evidence to support the phasing-out of treatment category II regimen for pulmonary tuberculosis in Peru'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver